Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report.

Clinical Sarcoma Research Pub Date : 2020-11-28 DOI:10.1186/s13569-020-00147-3

Juliette E Hamilton, Michael Alexander, Fergal C Kelleher

{"title":"Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report.","authors":"Juliette E Hamilton, Michael Alexander, Fergal C Kelleher","doi":"10.1186/s13569-020-00147-3","DOIUrl":null,"url":null,"abstract":"Background: Encephalopathy is an established side effect of the chemotherapeutic agent, ifosfamide, occurring in 10-30% of cases. The EEG commonly shows non-specific features of encephalopathy, and rarely shows frontal intermittent rhythmic delta activity (FIRDA).Case presentation: This is a case report of a 71 year old woman with pleomorphic sarcoma, who developed ifosfamide-induced encephalopathy with her second dose of ifosfamide. It shows the characteristic EEG findings that have been described previously with ifosfamide-induced encephalopathy and additionally the unusual and rare finding of FIRDA. This was followed up by a further EEG showing resolution of the encephalopathy, after administration of methylene blue, coinciding with rapid and complete resolution of her symptoms.Conclusion: The rapid resolution of the encephalopathy on the EEG after administration of methylene blue adds further evidence to its effectiveness as a treatment for the disorder.","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"10 1","pages":"25"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-020-00147-3","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-020-00147-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 6

Abstract

Background: Encephalopathy is an established side effect of the chemotherapeutic agent, ifosfamide, occurring in 10-30% of cases. The EEG commonly shows non-specific features of encephalopathy, and rarely shows frontal intermittent rhythmic delta activity (FIRDA).

Case presentation: This is a case report of a 71 year old woman with pleomorphic sarcoma, who developed ifosfamide-induced encephalopathy with her second dose of ifosfamide. It shows the characteristic EEG findings that have been described previously with ifosfamide-induced encephalopathy and additionally the unusual and rare finding of FIRDA. This was followed up by a further EEG showing resolution of the encephalopathy, after administration of methylene blue, coinciding with rapid and complete resolution of her symptoms.

Conclusion: The rapid resolution of the encephalopathy on the EEG after administration of methylene blue adds further evidence to its effectiveness as a treatment for the disorder.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

异环磷酰胺诱发的脑病:伴有额叶间歇性三角洲活动的脑电图，亚甲基蓝快速解决:1例报告。

背景:脑病是化疗药物异环磷酰胺的一个确定的副作用，发生在10-30%的病例中。脑电图通常显示脑病的非特异性特征，很少显示额叶间歇性节律性三角洲活动(FIRDA)。病例介绍:这是一个71岁的女性多形性肉瘤的病例报告，她在第二次服用异环磷酰胺后发展为异环磷酰胺诱导的脑病。它显示了先前描述的异环磷酰胺诱导脑病的特征性脑电图结果，以及不寻常和罕见的FIRDA发现。随后进行了进一步的脑电图检查，显示在给予亚甲基蓝后脑病得到了缓解，同时她的症状得到了迅速和完全的缓解。结论:亚甲基蓝治疗后脑病在脑电图上的快速消退进一步证明了其作为一种治疗疾病的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Sarcoma Research

自引率

0.00%

发文量

期刊介绍： Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.